

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/193714 A1

(51) International Patent Classification:

C12N 5/0775 (2010.01) A61P 1/16 (2006.01)
C12N 5/071 (2010.01) A61K 31/727 (2006.01)
A61K 35/407 (2015.01)

(21) International Application Number:

PCT/EP2020/058586

(22) International Filing Date:

26 March 2020 (26.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19165124.9 26 March 2019 (26.03.2019) EP
19201342.3 03 October 2019 (03.10.2019) EP

(71) Applicant: PROMETHERA BIOSCIENCES S.A./N.V.

[BE/BE]; Watson & Crick Hill, Rue Granbonpré, 11, 1435
Mont-Saint-Guibert (BE).

(72) Inventors: VEULEMANS, Nancy; Verbindingsstraat

13, 2830 Willebroek (BE). BARTHEL, Virginie; Rue
du NeufBois 21/303, 1490 Court-Saint-Etienne (BE).
SOKAL, Etienne; 30 a Ed Vandervaerenstraat, 1560
Hoeilaart (BE). THONNARD, Joëlle; Avenue des Flo-
ralies 17, 5030 Gembloux (BE). BELMONTE, Nathalie;
96 Corniche Fleurie, Le Plein Ciel, 06200 Nice (FR).
VAINILOVICH, Yelena; Hazenlaan 9, 3080 Tervuren
(BE).

(74) Agent: BRANTSANDPATENTS; Pauline Van Pottels-
berghelaan 24, 9051 Sint-Denijs-Westrem (BE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: ADULT LIVER PROGENITOR CELLS FOR TREATING ACUTE-ON-CHRONIC LIVER FAILURE




Fig. 1

(57) Abstract: The invention relates to the use of a composition comprising human adult liver- derived progenitor cells, such as heterologous human adult liver-derived progenitor cells (HALPC), for the treatment of a patient who has developed acute-on-chronic liver failure (ACLF) or is at risk of developing ACLF, wherein the treatment comprises a step of administering to said patient an amount of said composition which comprises a dose of 0.25 to 2.5 million said progenitor cells per kg body weight; wherein the composition is substantially free of an effective amount of an anticoagulant, and wherein the patient does not receive any co-treatment with an anticoagulant.

[Continued on next page]

WO 2020/193714 A1

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*